Health Care

Watch List Healthcare Stock: Galena Biopharma, Inc. (NASDAQ:GALE)

0 20

Galena Biopharma, Inc. (NASDAQ:GALE) closed its last session at $0.3302 with the change of -5.9527%. The market capitalization of the company is $70.65M with an average Volume of 8.19 million shares. The stock currently has its 52-Week High range of $2.4900 and 52-week low range of $0.2800. The Price to Book (P/B) ratio stands at 3.1631. The stock traded total quantity of 4.78 million shares.

Currently Galena Biopharma, Inc. (GALE) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “2″ Analysts”. “0” rated “Sell” for the company. “2” said the company as a “Hold”. Overweight rating was given by “0” and Underweight rating was given by “0”.

Analysts are expecting that the company to achieve $1.13 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $2.00 however minimum price target advised by analysts is $0.40. The Median price target for the stock is measured at $1.00.

Presently, Analysts decided consensus EPS estimate of $-0.04 for present quarter and one month ago projected EPS estimate was at $-0.05. If we take a look at back 3 month ago, consensus EPS estimate was $-0.06.

A current consensus EPS estimate for next quarter is at $-0.04 and 3 month ago EPS forecast was $-0.06. Have a look at back 1 month ago, consensus EPS forecast was seen at $-0.04.

For current fiscal year, most recent EPS estimate is set at $-0.16 based on Analyst consensus and three month ago consensus EPS opinions was at $-0.28. During period one month ago, consensus EPS forecast was decided at $-0.20.

A current consensus EPS projection for next fiscal year is observed at $-0.13 and one month ago consensus EPS forecast was at $-0.15. Take a look at back three month ago, consensus EPS estimate opinions was decided at $-0.24 by analysts.

One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 2 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 0. 2 advised the “Hold” rating about this stock. 0 revealed “Sell” signal and “Underweight” rating was declared by 0.

Three Months Ago, Analysts recommended an average brokerage rating of Buy derived from brokerage firms, according to FactSet. 4 said a “Buy Rating” and 1 announced “Overweight Rating”. 0 advised “Hold Rating” regarding the stock. 0 announced “Sell Rating” and 0 disclosed “Underweight Rating”.

About the author / 

Leave a reply

Your email address will not be published. Required fields are marked *

Advirtisement

About Us

WSnews4investors is the influential source for financial news and Opinion Company with content which delivered over the Internet. WSnews4investors is a dynamic and innovative financial media outlet that empowers investors with high-quality, unique content that is coveted by Wall Street’s traders.

Newsletter